Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

US11951166B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Sabine Hoff · Potsdam, DE
• Lars Röse · Berlin, DE
• Dieter Zopf · Marburg, DE
• Fabian Kiessling · Aachen, DE
• Wiltrud LEDERLE · Aachen, DE
• Dennis DOLESCHEL · Aachen, DE

Key dates

• Filing date: May 25, 2018
• Grant date: Apr 9, 2024
• Expiry date: May 25, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.